Literature DB >> 21659721

Serum insulin, cortisol, leptin, neuropeptide Y, galanin and ghrelin levels in epileptic children receiving valproate.

Ali Cansu1, Ayse Serdaroglu, Orhun Camurdan, Tuba Hırfanoğlu, Peyami Cinaz.   

Abstract

AIMS: The objective of this study was to investigate the cause of valproate (VPA)-associated weight gain in children.
METHODS: Eighteen children (10.94 ± 3.78 years) with epilepsy were assigned to VPA therapy. Serum levels of glucose, insulin, cortisol, leptin, neuropeptide Y (NPY), galanin and ghrelin were assessed before (month 0) and after 18 months of therapy. Eighteen age- and gender-matched patients (10.78 ± 3.95 years) were enrolled as the control group.
RESULTS: Excess per capita weight of 2.3 kg was determined in the children receiving VPA over 18 months compared to the control group. In these patients, a statistically significant increase in standardized weight score, Homeostasis Model Assessment index, serum leptin, NPY and galanin values was determined at the 18th month compared to those before VPA treatment and in the control group, and there was also a significant decrease in ghrelin values.
CONCLUSION: Increased serum levels of leptin, NPY and galanin play an important role in VPA-associated weight gain in children. While ghrelin is not directly associated with weight gain, its serum levels decline as a response to weight gain.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21659721     DOI: 10.1159/000327367

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  4 in total

Review 1.  Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research.

Authors:  Kevin G Bath; Helen E Scharfman
Journal:  Epilepsy Behav       Date:  2013-01-08       Impact factor: 2.937

2.  Inactivation of the constitutively active ghrelin receptor attenuates limbic seizure activity in rodents.

Authors:  Jeanelle Portelli; Leen Thielemans; Luc Ver Donck; Ellen Loyens; Jessica Coppens; Najat Aourz; Jeroen Aerssens; Katia Vermoesen; Ralph Clinckers; Anneleen Schallier; Yvette Michotte; Dieder Moechars; Graham L Collingridge; Zuner A Bortolotto; Ilse Smolders
Journal:  Neurotherapeutics       Date:  2012-07       Impact factor: 7.620

Review 3.  Preclinical evidence of ghrelin as a therapeutic target in epilepsy.

Authors:  Tongtong Ge; Wei Yang; Jie Fan; Bingjin Li
Journal:  Oncotarget       Date:  2017-06-02

Review 4.  Targeting the Ghrelin Receptor as a Novel Therapeutic Option for Epilepsy.

Authors:  An Buckinx; Dimitri De Bundel; Ron Kooijman; Ilse Smolders
Journal:  Biomedicines       Date:  2021-12-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.